TELA Bio Reports Slowed Q1 Revenue Growth, Increased Net Loss Amid Nasdaq Delisting Concern
TELA sits 99% above its 52-week low of $0.501.
Summary
TELA Bio reported modest 3% revenue growth and a higher net loss for Q1 2026, intensifying concerns as its stock remains below the Nasdaq minimum bid price, despite management reiterating full-year guidance.
Key Events · Earnings and Guidance · TELA
-
Q1 2026 Financial Performance
Revenue grew a modest 3% year-over-year to $19.1 million, a significant slowdown from 2025's 16% growth, while net loss increased to $12.3 million.
-
Reiterated Full-Year Guidance
Management maintained its projection for at least 8% revenue growth for full-year 2026, implying an expected acceleration in performance after a weak first quarter.
-
Nasdaq Compliance Pressure
The modest Q1 results add pressure to the company's ongoing efforts to regain compliance with Nasdaq's $1.00 minimum bid price requirement, following a deficiency letter in March.
-
New Product Launch
TELA Bio announced the U.S. commercial launch of OviTex LTR, a fully resorbable hernia repair solution, on April 1st, expanding its product portfolio.
Analysis · TELA · Industrial Applications And Services
TELA Bio's first-quarter 2026 results show a significant deceleration in revenue growth to 3% year-over-year, coupled with an increased net loss. This performance is concerning, especially as the company is currently under a Nasdaq deficiency notice for its stock trading below $1.00. While management reiterated its full-year revenue growth guidance of at least 8%, implying a strong recovery in subsequent quarters, the immediate financial performance adds pressure to its compliance efforts.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 990 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELA was trading at $1.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $45.6M. The 52-week trading range was $0.50 to $2.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.